The Clinical Landscape Is Changing
Learn More
25
Billion dollar clinical burden of chronic wounds (US)
80
Percent of amputations caused by hard-to-heal wounds
5
Billion dollar advanced wound care market worldwide
5000
People successfully treated in Israel with CureXcell®

 

About Us

Macrocure Ltd. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).

 
Learn More

curexcell

The Technology

CureXcell® is comprised of a mixture of white blood cells including monocytes/macrophages, neutrophils and lymphocytes obtained from young (18-40 yrs old) healthy donor blood which is activated by a safe and simple yet patented process.

CureXcell® replenishes the imbalanced inflammatory environment in the non-healing wound with functionally-active immune cells which release the necessary growth factors and are capable of phagocytosis of bacteria and dead cells in the wound bed, processes that are important for healing.

Learn More

Clinical Trials

CureXcell® is currently in two pivotal, Phase 3, double-blind clinical trials. Clinical sites in the US, Canada and Israel are actively recruiting participants in this study.
Learn More

Watch Our Process

Wound healing is a dynamic process that involves the interaction of many cell types, the extracellular matrix, and chemical mediators.

Latest News & Events


25
Percent of people with Diabetes who will develop a foot ulcer
55
Growth factors & cytokines idetified & quantified in CureXcell®
500
Patients in our Phase III clinical trials, the largest BLA study of its kind to date
2030
Expiration year under current patent protection